AbbVie Retained Earnings (Accumulated Deficit) 2012-2026 | ABBV

AbbVie retained earnings (accumulated deficit) for the quarter ending March 31, 2026 were $-14.234B, a 186.74% increase year-over-year.

  • AbbVie retained earnings (accumulated deficit) for 2024 were $-7.9B, a 690% increase from 2023.
  • AbbVie retained earnings (accumulated deficit) for 2023 were $-1B, a 120.9% decline from 2022.
  • AbbVie retained earnings (accumulated deficit) for 2022 were $4.784B, a 52.99% increase from 2021.

AbbVie Retained Earnings (Accumulated Deficit) 2012-2026 | ABBV

  • AbbVie retained earnings (accumulated deficit) for 2024 were $-7.9B, a 690% increase from 2023.
  • AbbVie retained earnings (accumulated deficit) for 2023 were $-1B, a 120.9% decline from 2022.
  • AbbVie retained earnings (accumulated deficit) for 2022 were $4.784B, a 52.99% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B